Digimarc Corporation (DMRC) Q3 Revenue Falls to $6.4M, ARR to $10.8M

Digimarc (DMRC) reported Q3 2026 revenue of $6.4M, down from $7.6M a year earlier. Annual recurring revenue (ARR) fell to $10.8M from $15.8M, attributed to contract expirations. Net loss was $8.1M, or $0.36 per share, slightly improved from the prior year. Cash and securities increased to $22.1M, but free cash flow usage rose to $4.3M.

Original reporting
Published Nov 12, 2026, 9:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 12, 2026, 9:08 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Digimarc Corporation (DMRC) Q3 Revenue Falls to $6.4M, ARR to $10.8M — source image
Decision brief

The 30-second read

$DMRCBearishLow
01

Why it matters

The earnings miss is likely to trigger a short‑term sell‑off, but the sizable cash position could support a turnaround if new contracts are won.

02

Market read

Microcap earnings miss with declining recurring revenue; limited broader market impact.

03

What to watch

Strong cash balance of $22.1M provides runway for strategic acquisitions or R&D investment.

Relevance 6/10Novelty 6/10Timing: after-hours

Background

Digimarc disclosed its Q3 2026 financial results, showing a decline in revenue and ARR due to contract expirations.

Company-level read

Ticker impact

$DMRCBearishMedium confidence
Context

Q3 2026 revenue fell 16% to $6.4M and ARR dropped to $10.8M, indicating weaker sales and contract expirations.

Expected impact

downward pressure as investors price in weaker recurring revenue

Evidence & confidence

The company posted a significant revenue drop and lower ARR, with cash still ample but no new growth catalyst disclosed.

Market effects

Highlights softness in the digital watermarking and data integrity niche, potentially pressuring peers.

Limited to U.S. microcap investors; no broader regional effect.

Minimal; the company is small and sector‑specific.

Counterpoint

If the company can secure new multi‑year contracts in 2027, the current dip may be a buying opportunity at lower valuations.

Key entities

  • Digimarc Corporation

    Provider of digital watermarking and data integrity solutions, ticker DMRC.

Related articles

$DMRCMed

Digimarc Reports Third Quarter 2026 Financial Results

Digimarc Corp (DMRC) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Digimarc Reports Third Quarter 2026 Financial Results Narrowing our Aperture to Accelerate Beaverton, Ore. – November 12, 2026 – D igimarc Corporation (NASDAQ: DMRC) reported financial results for the third quarter ended September 30, 2026 . "Last quarter we said our

$DMRCMed

Digimarc Reports Second Quarter 2026 Financial Results

Digimarc Corp (DMRC) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Digimarc Reports Second Quarter 2026 Financial Results Narrowing our Aperture to Accelerate Beaverton, Ore. – August 13, 2026 – D igimarc Corporation (NASDAQ: DMRC) reported financial results for the second quarter ended June 30, 2026 . "We are already starting to se

$NOKMed

LightCounting:: November 2026 Nokia SReXperts

Nokia hosted its SReXperts/Wavelengths conference in November 2026, focusing on AI's impact on connectivity and its solutions for customers. The company reported strong Q3 2026 earnings, with AI & Cloud sales doubling year-over-year and $1.7 billion in new orders. Nokia expects 25-30% growth in its Optical and IP Networks businesses in 2027. The company aims to help telecom operators adapt to AI-driven changes and capitalize on new opportunities.

$IBRXLow

IBRX Stock Eyes Best Year Ever: Founder Teases 12 Months Of ‘Stealth’ NantWorks Reveals — Cancer Tech, AI Chips And Satellites

ImmunityBio (IBRX) reported a 53% increase in Q3 net product revenue to $48.7M, with 92% growth for the first nine months. The company is testing its drug Anktiva for sepsis and aims to expand FDA approval for bladder cancer. NantWorks, led by Patrick Soon-Shiong, plans a blockchain-based exchange for tokenized securities. IBRX stock has risen 195% over the past year, with bullish retail sentiment on Stocktwits.